Bryce Point Capital, LLC Neurocrine Biosciences Inc Transaction History
Bryce Point Capital, LLC
- $133 Billion
- Q1 2025
A detailed history of Bryce Point Capital, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bryce Point Capital, LLC holds 6,782 shares of NBIX stock, worth $744,324. This represents 0.63% of its overall portfolio holdings.
Number of Shares
6,782Holding current value
$744,324% of portfolio
0.63%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
646Shares Held
94.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.56 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.11 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$537 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$331 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$279 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...